Medicare Advantage rates boost UnitedHealth
CMS increased the final Medicare Advantage payment rate to a 2.48% uplift, a larger increase than originally proposed that supported UnitedHealth’s stock. (insidermonkey.com) Coverage also notes UnitedHealth faces ongoing DOJ investigations and has seen a substantial market‑capitalisation decline from prior highs. (insuranceasia.com)
The Centers for Medicare and Medicaid Services raised Medicare Advantage payment rates more than insurers expected, giving UnitedHealth a near-term lift. (cms.gov) On April 6, 2026, the agency said average Medicare Advantage payments will rise 2.48% in 2027, or more than $13 billion. That was above the 2.23% increase proposed in January. (cms.gov) Medicare Advantage is the private-plan version of Medicare, and insurers like UnitedHealth get a fixed monthly payment for each member. Higher government rates can help offset rising medical costs and reduce pressure on benefits or margins. (cms.gov) Investors treated the final notice as good news for the sector. CNBC reported the bigger-than-expected increase boosted health insurer shares because Wall Street had feared a tighter reimbursement update. (cnbc.com) The rate decision landed after a bruising stretch for UnitedHealth. In April 2025, the company cut its annual profit forecast and its shares fell 19% in one session after it warned that medical costs were running higher than expected. (cnbc.com) UnitedHealth has also been dealing with federal scrutiny beyond routine rate-setting. The company said on July 24, 2025, that it had begun complying with formal criminal and civil requests from the Department of Justice tied to aspects of its Medicare business. (unitedhealthgroup.com) UnitedHealth said it had “full confidence” in its practices and would cooperate with the department. In a separate May 21, 2025 statement, UnitedHealthcare said the Justice Department had previously declined to pursue certain allegations after a multi-year review. (unitedhealthgroup.com, unitedhealthgroup.com) The company has faced antitrust pressure, too. The Justice Department sued in November 2024 to block UnitedHealth’s proposed acquisition of Amedisys, arguing the deal would reduce competition in home health and hospice markets. (justice.gov) Even after the rate boost, the stock has not recovered to its prior peak. CompaniesMarketCap data show UnitedHealth’s highest closing share price was $615.84 on November 11, 2024; by April 2026, its market value was about $283 billion. (companiesmarketcap.com, companiesmarketcap.com) For now, the government’s new Medicare Advantage rate gives UnitedHealth something it has not had much of lately: a policy decision that moves in its favor while the legal and cost pressures keep hanging over the company. (cms.gov, unitedhealthgroup.com, cnbc.com)
